Flunarizine is a highly potent inhibitor of cardiac hERG potassium current

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 2, 2006, Pages 211-220

  Trepakova, Elena S ^a   Dech, Spencer J ^a   Salata, Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiac potassium current; Flunarizine; hERG

Indexed keywords

FLUNARIZINE; POTASSIUM CHANNEL HERG; VOLTAGE GATED CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; ERG1 POTASSIUM CHANNEL; POTASSIUM; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; EPILEPSY; GENE; GENE EXPRESSION; HERG GENE; IC 50; MIGRAINE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL VASCULAR DISEASE; POTASSIUM CURRENT; PRIORITY JOURNAL; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HAMSTER; HEART; HEART FUNCTION TEST; HUMAN; METABOLISM; PATCH CLAMP; PHYSIOLOGY;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL CULTURE TECHNIQUES; CELL LINE; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUNARIZINE; HEART; HUMANS; MOLECULAR STRUCTURE; PATCH-CLAMP TECHNIQUES; POTASSIUM; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 33746430610     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000200810.18575.80     Document Type: Article

References (48)

1. Holmes B, Brogden RN, Heel RC, et al. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1984;27:6-44.
2. de Bock GH, Eelhart J, van Marwijk HW, et al. A postmarketing study of flunarizine in migraine and vertigo. Pharm World Sci. 1997;19:269-274.
3. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2004(3):CD003226.
4. Norium™ label. SK+F, Eskayef Bangladesh Ltd. Dhaka, Bangladesh.
5. De Cree J, Geukens H, Verhaegen H. [Effect of flunarizine (sibelium) on the arterial blood flow (author's transl)]. MMW Munch Med Wochenschr. 1978;120:627-630.
6. Moglia A, Bergamasco B, Di Perri R, et al. Flunarizine as add-on therapy in epilepsy. Crossover study vs placebo. Funct Neurol. 1986;1:547-550.
7. Nagakawa Y, Akedo Y, Kaku S, et al. Effect of flunarizine on volume flow of the common carotid artery, peripheral hemodynamics, erythrocyte deformability and platelet function. Arzneimittelforschung. 1989;39:82-85.
8. 2+ channel blockade by flunarizine in ventricular myocytes of the guinea-pig. Eur J Pharmacol. 1996;296:189-197.
9. Akaike N, Kostyuk PG, Osipchuk YV. Dihydropyridine-sensitive low-threshold calcium channels in isolated rat hypothalamic neurones. J Physiol. 1989;412:181-195.
10. 2+ channels in rat aorta smooth muscle cells in primary culture. Circ Res. 1990;67:469-480.
11. Nakayama K, Kasuya Y. Selective abolition of Ca-dependent responses of smooth and cardiac muscles by flunarizine. Jpn J Pharmacol. 1980;30:731-742.
12. Van Nueten JM, Van Beek J, Janssen PA. Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch Int Pharmacodyn Ther. 1978;232:42-52.
13. 2 alpha and noradrenaline on calcium exchange and contraction in rat mesenteric arteries and their sensitivity to calcium entry blockers. Br J Pharmacol. 1982;75:229-236.
14. Pukhal'skaya TG, Kolosova OA, Men'shikov MY, et al. Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine. Bull Exp Biol Med. 2000;130:633-635.
15. Tytgat J, Pauwels PJ, Vereecke J, et al. Flunarizine inhibits a high-threshold inactivating calcium channel (N-type) in isolated hippocampal neurons. Brain Res. 1991;549:112-117.
16. + channel blocking effects. Basic Clin Pharmacol Toxicol. 2004;94:79-88.
17. +-channel blockers in isolated Purkinje neurons of rat cerebellum. Neuroscience. 1993;54:575-585.
18. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA. 2000;97:12329-12333.
19. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 1996;94:817-823.
20. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol Heart Circ Physiol. 1997;273:H2534-H2538.
21. Walker BD, Singleton CB, Bursill JA, et al. Inhibition of the human ethera-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol. 1999;128:444-450.
22. Zhou ZF, Vorperian VR, Gong QM, et al. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol. 1999;10:836-843.
23. Kiss L, Bennett PB, Uebele VN, et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol. 2003;1:127-135.
24. Imredy JP, Irving WD, Clouse HK, et al. Electrophysiological and pharmacological characterization of a cell line stably expressing hKCNQ1 and hKCNE1 potassium channels. Biophys. 2004:132a.
25. Hamill OP, Marty A, Neher E, et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100.
26. Zhou ZF, Gong QM, Ye B, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J. 1998;74:230-241.
27. Dubin AE, Nasser N, Rohrbacher J, et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen. 2005;10:168-181.
28. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature. 1996;379:833-836.
29. Rampe D, Murawsky MK, Grau J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther. 1998;286:788-793.
30. Tsujimae K, Suzuki S, Yamada M, et al. Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. Eur J Pharmacol. 2004;493:29-40.
31. Carmeliet E, Mubagwa K. Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol. 1998;70:1-72.
32. + channel. J Pharmacol Exp Ther. 2001;299:1007-1012.
33. Ekins S, Crumb WJ, Sarazan RD, et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther. 2002;301:427-434.
34. Lavrijsen K, van Houdt J, van Dyck D, et al. Comparative metabolism of flunarizine in rats, dogs and man: an in vitro study with subcellular liver fractions and isolated hepatocytes. Xenobiotica. 1992;22:815-836.
35. Meuldermans W, Hendrickx J, Hurkmans R, et al. Excretion and metabolism of flunarizine in rats and dogs. Arzneimittelforschung. 1983;33:1142-1151.
36. Kariya S, Isozaki S, Uchino K, et al. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996;19:1511-1514.
37. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475-495.
38. Canadian Adverse Drug Reaction Information System. 2003. www.cbc.ca/news/adr/database.
39. Verduyn SC, Vos MA, Gorgels AP, et al. The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart. J Cardiovasc Electrophysiol. 1995;6:189-200.
40. Vos MA, Gorgels AP, Leunissen JD, et al. Flunarizine allows differentiation between mechanisms of arrhythmias in the intact heart. Circulation. 1990;81:343-349.
41. Jonkman FA, Boddeke HW, van Zwieten PA. Protective activity of calcium entry blockers against ouabain intoxication in anesthetized guinea pigs. J Cardiovasc Pharmacol. 1986;8:1009-1013.
42. +-overload by flunarizine. Int Angiol. 1984;3:25-31.
43. Bril A, Gout B, Bonhomme M, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther. 1996;276:637-646.
44. Bril A, Faivre JF, Forest MC, et al. Electrophysiological effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations. J Pharmacol Exp Ther. 1995;273:1264-1272.
45. Zhang S, Sawanobori T, Hirano Y, et al. Multiple modulations of action potential duration by different calcium channel blocking agents in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 1997;30:489-496.
46. Ks, in guinea-pig ventricular myocytes. Br J Pharmacol. 1999;128:1733-1738.
47. Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther. 1986;237:9-17.
48. Manouvrier J, Sagot M, Caron C, et al. Nine cases of torsade de pointes with bepridil administration. Am Heart J. 1986;111:1005-1007.